INVIEW Oncoprofiling (728 genes)

INVIEW Oncoprofiling - 728

Validated cancer panel for analysis of 728 key cancer-specific genes from tissue biopsy samples and genomic DNA

INVIEW Oncopprofiling is one is the most comprehensive gene panel available for optimised detection of tumour-specific genomic alterations. The oncology panel is optimised for formalin-fixed paraffin embedded (FFPE) or fresh-frozen tissue samples, as well as genomic DNA samples, to deliver accurate genomic information on the status of clinically relevant driver mutations. This solid tumour panel uniformly and reproducibly covers the entire exons of about 728 characterised cancer genes, including tumour activators, tumour suppressors and biomarkers for drug resistance.

>> Get Quote / Order

>> order Barcodes

>> Industrial-grade

Applications

Comparative analysis of data from tissue biopsy and liquid biopsy (INVIEW Liquid Biopsy Oncoprofiling)
Cancer screening by detection of well-known tumour-associated mutations such as driver mutations
Determination of most important mutations for further studies
Estimation of immune checkpoint inhibitor immunotherapy response via tumour mutational burden (TMB) biomarker analysis with tumour-only samples (paired matched healthy/normal control sample not necessarily required)

INVIEW Oncopanel 728 is suitable for clinical applications like:

Molecular stratification
Detection of resistance genes
Guidance for treatment decisions
Assignment of patients to clinical trials
Post-treatment follow-up, especially for monitoring of multiple mutations

Highlights

Highly uniform coverage of all exons in 728 cancer-associated genes
Detection of relevant single nucleotide variations (SNVs) and insertions and deletions (InDels), structural rearrangements and copy number variations (CNV) in genes, selected promotor regions, miRNAs, and extra-exonic variants
Determination of tumour mutational burden (TMB) status of the patient
Ultra-sensitive detection levels down to 1% allele frequency
Proprietary protocols for low-input DNA library preparation from challenging tissue and FFPE samples

>> FAQ's Oncoprofiling

>> Sample Submission

>> demo report

Product Specifications & Ordering

Accepted starting material

DNA
FFPE tissue
Fresh-frozen tissue

Full service package offered by INVIEW Oncopanel 728 including

Validated next-generation sequencing (NGS) cancer gene panel for analysis of key tumour-associated mutations in 728 protein-coding genes, selected promoter regions, miRNAs, and 282 extra-exonic variants (introns, regulatory regions, untranslated regions (UTRs) and intergenic regions)
Reproducible detection of single nucleotide polymorphisms (SNPs), insertions and deletions (InDels)
Determination of tumour mutational burden (TMB) based on all coding synonymous and non-synonymous eligible somatic mutations with in silico filtering of known and predicted germline variants
Highly efficient target enrichment with latest Agilent SureSelect technology
Target enrichment approach outcompetes common PCR-based enrichment with very uniform coverage and all exons of the genes covered
Industry-leading sequence coverage and uniformity
Detection of variants with sensitivity levels down to 1%^#
Optimised protocols for low-input DNA library preparation from FFPE or fresh-frozen tissue samples
Analysis of copy number variations (CNVs) possible*

*CNV analysis should be performed in paired analysis of tumour versus matched normal tissue which is used as reference. In the case of tumour FFPE samples, we strongly recommend sending a healthy tissue FFPE sample from the same patient. Alternatively, tumour FFPE samples from at least seven other patients can be sent.

^#Depending on the input DNA quality and genomic region LOD might be >1%

For fresh frozen tissue, we strongly advise that blood or healthy tissue from the same patient is sent. Alternatively, fresh frozen tissue from at least seven other patients or controls is recommended.

Technology

Hybridisation-based target capture using Eurofins Genomics optimised protocols and latest Agilent SureSelect technology
Next-generation sequencing on Illumina platform